Brain Cancer Halted in Mice Using Antihistamine Drug

Glioblastoma is the most prevalent and also the most lethal type of brain tumour in adults, with no curative treatment currently available. Glioblastomas cannot be surgically completely excised, as the tumour cells are adept at invading tissues and spreading around the brain. In addition, glioblastoma cells are extremely resistant to existing drug therapies. For a long time, researchers have been...

Triclosan, a Common Antimicrobial Ingredient in Toothpaste, Soaps, Linked to Colonic Inflammation, Altered Gut Microbiota

A large research team led by senior author Guodong Zhang at the University of Massachusetts Amherst reports that the antimicrobial ingredient triclosan, found in hand soaps and toothpastes among other products, could have adverse effects on colonic inflammation and colon cancer by altering gut microbiota, the microbes found in our intestines. The study reported in Science...

Researchers putting the brakes on lethal childhood cancer

Malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal childhood cancers. Although rare — about 20 to 25 new cases are diagnosed annually in the United States — there is no standard effective treatment for the disease, which is driven by loss of an anti-cancer protein called SNF5. The chances are very small that a child will...

Inovio publishes early positive results for dBiTEs cancer/leukemia approach

BiTE ( bispecific T-cell engager ) therapy is a relatively new approach in immunotherapy for cancer. BiTEs are used to help direct tumor killing cells to cancerous tumors, and the effect ranges from slowing cancer tumor growth, to completely halting it. One problem with the current BiTE approach is the cost of generating the BiTE cells. Inovio thinks they...

Eureka Therapeutics publishes preclinical study demonstrating new t-cell cancer therapy

Eureka Therapeutics has published a proof-of-concept study in OncoImmunology entitled “Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.” Inspired by the results of checkpoint therapies such as PD-1, which reduce immune system suppressing aspects of cancerous tumors, Eureka developed a therapy that aims to deplete the the regulatory t-cells within tumors as means...

UC San Diego School of Medicine and Fate Therapeutics begin a clinical trial for stem cell cancer cure

In a first-of-its-kind trial in the United States, a stem cell-derived natural killer cell immunotherapy is being tested in people with incurable cancer. This natural killer immunotherapy trial is the first in the United States to use cells derived from induced pluripotent stem (iPS) cells. iPS cells are similar to their embryonic counterparts, in that they can develop into...

UCARTCS1, the first allogenic T-Cell treatment for Multiple Myeloma, has been cleared by the FDA to begin Phase 1 trials.

Those suffering of Multiple Myeloma have reason for hope today, as the first treatment using allogenic genetically modified CAR t-cells has passed the Investigational New Drug process with the FDA, allowing Cellectis to proceed with Phase 1 trials. The current approach to treating multiple myeloma requires the patient's blood to be extracted and processed, using an expensive process and specialized...